新达制药申报的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)于近期获得批准，有利于丰富公司降糖制剂系列， 有利于提升公司综合竞争力。 山东新华制药（000756）股份(00719)发布公告，近日，公司的全资子公司山东淄博新达制药有限公司 收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。 本品配合饮食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者 的血糖控制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。本品为《国家基本医疗保险、工伤保 险和生育保险药品目录(2025年)》乙类品种。根据相关统计数据，2024年中国公立医疗机构沙格列汀二 甲双胍缓释片销售额约为人民币4.19亿元。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，近日，公司的全资子公司山东淄博新达制药有限 公司收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。 本品配合饮食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者 的血糖控制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。本品为《国家基本医疗保险、工伤保 险和生育保险药品目录(2025年)》乙类品种。根据相关统计数据，2024年中国公立医疗机构沙格列汀二 甲双胍缓释片销售额约为人民币4.19亿元。 新达制药申报的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)于近期获得批准，有利于丰富公司降糖制剂系列， 有利于提升公司综合竞争力。 ...

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is facing regulatory scrutiny due to discrepancies in the use of raised funds compared to what was disclosed in its IPO prospectus, leading to a warning for its former board secretary and ongoing financial challenges for the company [1][2][3]. Group 1: Regulatory Issues - Zhejiang Securities Regulatory Bureau found that Dongya Pharmaceutical's actual use of raised funds did not align with the disclosures made in its IPO prospectus, and the company failed to follow internal review procedures for these changes [2]. - The company has been ordered to rectify these issues, and the violations will be recorded in the securities market's integrity archives [2][3]. Group 2: Financial Performance - Dongya Pharmaceutical's revenue for 2022, 2023, 2024, and the first half of 2025 were reported at 1.18 billion, 1.36 billion, 1.20 billion, and 416 million respectively, with year-on-year growth rates of 65.62%, 15.00%, -11.66%, and -35.85% [4]. - The net profit attributable to shareholders for the same periods was 104 million, 121 million, -101 million, and -30.23 million, with year-on-year growth rates of 52.46%, 16.11%, -183.02%, and -193.09% [4]. - The company's debt-to-asset ratio has increased from 25.56% in 2022 to 47.70% in the first half of 2025, indicating rising financial leverage [4]. Group 3: Business Challenges - Dongya Pharmaceutical's core antibacterial drug business is under significant pressure due to the government's "antibiotic restriction orders," which have limited the market space for antibacterial drugs [5][6]. - The company has attempted to implement a "raw material drug formulation integration" strategy, but progress has been slow, with only one of over ten submitted formulations receiving approval [7]. - The existing product structure remains heavily reliant on antibacterial drugs, exposing the company to substantial market and policy risks [7].